Introduction
Egalet (NASDAQ:EGLT) is a pharmaceutical company focused on developing and marketing treatments to address the needs of patients living with pain. While pain management is important, too often opioid treatments are abused. In response to the FDA's call for abuse-deterrent compounds, Egalet is focusing its research and marketing on products that meet the pain management needs of patients while also designing compounds that are more difficult to be abused. Prior to the Arymo ER approval, Egalet already had two marketed drugs which have experienced strong sales. Despite the labeling concerns, Egalet's recent approval, current products and promising pipeline offer investors great value. This is particularly true considering the brutal, and I believe overdone, selloff that has occurred in the stock.
